½ÃÀ庸°í¼­
»óǰÄÚµå
1764873

ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ¿¹Ãø - Áö¿ªº° ºÐ¼® - Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚº°(-2031³â)

North America Organ Preservation Solution Market Forecast to 2031 - Regional Analysis - by Product, Application, Type, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº 2023³â¿¡ 1¾ï 2,323¸¸ 9,050´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 2¾ï 2,611¸¸ 8,820´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2031³âÀÇ CAGRÀº 8.0%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

Àå±â ÀÌ½Ä ¿ä±¸ Áõ°¡°¡ ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀ» µÞ¹Þħ

ÀϺΠ¸¸¼º ÁúȯÀº ½ÉÀå, Æó, °£, ½ÅÀå ¹× ±âŸ Àå±âÀÇ ±â´É¿¡ ¼Õ»óÀ» ÁÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ½Ä»ýȰÀÇ È¥¶õÀº ½ÅÀå°ú °£ ÁúȯÀÇ ¹ßº´À¸·Î À̾îÁ® Àå±â ºÎÀüÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°è Àα¸ÀÇ ¾à 10%°¡ ¸¸¼º ½ÅÀå ÁúȯÀÇ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ¹Ì±¹ º¸°Ç»çȸº¹ÁöºÎ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 7¸í Áß 1¸í ÀÌ»ó(¾à 15%, 3¸¸ 7,000¸í)ÀÌ ¸¸¼º ½ÅÀ庴¿¡ °É·Á ÀÖ´Ù°í ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. Scientific Registry of Transplant RecipientsÀÇ º¸°í¼­¿¡ µû¸£¸é, ½ÉºÎÀü Ä¡·á°¡ ¼º°øÇß´ÂÁö ¿©ºÎ¿¡ °ü°è¾øÀÌ »õ·Î¿î ½ÉÀå À̽ÄÀÇ ´ë»óÀÌ µÇ´Â Èĺ¸ÀÚÀÇ ¼ö´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2018³âºÎÅÍ 2020³â±îÁö Á¤Ã¼±â¸¦ °Þ°í 2020³â¿¡´Â ¼ÒÆø °¨¼Ò(2019³â 4,087°Ç¿¡¼­ 2020³â 4,000°ÇÀ¸·Î)Çß´ø ½Å±Ô ½ÉºÎÀü »ç·Ê´Â 2021³â¿¡ 4,373°ÇÀ¸·Î Áõ°¡Çß½À´Ï´Ù. United Network for Organ SharingÀº ¹Ì±¹ÀÇ Àå±â ÀÌ½Ä °Ç¼ö°¡ 4¸¸ 6,000°ÇÀ» ³Ñ¾ú´Ù°í º¸°íÇßÀ¸¸ç, 2022³â ´ëºñ 8.7% ÀÌ»ó Áõ°¡ÇÑ »ç»ó ÃÖ´ëÄ¡¸¦ ´Þ¼ºÇß´Ù°í º¸°íÇß½À´Ï´Ù. Àå±â ´ë±â ¸®½ºÆ®¿¡ ½Ç·Á Àִ ȯÀÚ´Â ÀϹÝÀûÀ¸·Î ¸»±â Àå±â ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, QOL¿¡ Å« ¿µÇâÀ» ÁÖ¾î ÀλýÀÇ ³¡¿¡ °¡±î¿öÁö°í ÀÖÀ½À» ³ªÅ¸³»°í ÀÖÀ» °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. Àå±â º¸Á¸ ¿ë¾×Àº Àå±âÀÇ »ýÁ¸ ´É·Â°ú ±â´ÉÀ» ÀÏÁ¤ ±â°£ À¯ÁöÇϱâ À§ÇØ »ç¿ëµÇ¸ç Àå±âÀÇ ¼ö¼Û°ú ÈÄ¼Ó ¼öÇýÀÚ¿¡°Ô À̽ÄÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

ºÏ¹Ì Àå±â º¸Á¸ ¿ë¾× ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº ¼¼°è ÃÖ´ëÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀ¸·Î ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. National Chronic Kidney Disease fact sheet¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 2021³â¿¡ ¾à 37,000¸íÀÌ ¸¸¼º ½ÅÀ庴À» ¾Î°í ÀÖ½À´Ï´Ù.

2024³â 6¿ù ¹Ì±¹ ½ÅÀå ±â±Ý(American Kidney Fund, Inc.)Àº ÃÖ´ë 3¸¸ 7,000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÅÀ庴À» ¾Î°í ÀÖÀ¸¸ç, ¾à 808,000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÅºÎÀüÀ» ¾Î°í ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ½ÅÀ庴ÀÇ À¯º´·üÀº »ó½Â °æÇâ¿¡ ÀÖÀ¸¸ç ÇöÀç ¹Ì±¹ ¼ºÀÎÀÇ 7¸í Áß 1¸í(14%)ÀÌ ÀÌȯµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÀ庴À» ¾Î°í ÀÖ´Â 10¸í Áß 9¸íÀº ÀÚ½ÅÀÌ ½ÅÀ庴ÀÓÀ» ±ú´ÝÁö ¸øÇÏ°í ½ÅÀå ±â´ÉÀÌ ÇöÀúÈ÷ ÀúÇÏµÈ »ç¶÷ÀÇ 3¸í Áß 1¸íµµ ÀÚ½ÅÀÌ ½ÅÀ庴ÀÓÀ» ±ú´ÝÁö ¸øÇϰí ÀÖ½À´Ï´Ù. 2023³â¿¡´Â ½ÅÀåÀ̽ÄÀ» ¹ÞÀº °ÍÀº ºÒ°ú 2¸¸ 7,332¸íÀ¸·Î ±× Áß 6,290¸íÀº »ýü ±âÁõÀڷκÎÅÍÀÇ °ÍÀ̾ú½À´Ï´Ù. 2022³â 4¿ù, TransMedics Group, Inc.´Â ¼øÈ¯ Á×À½(DCD) ÈÄ ±âÁõÀÚÀÇ ±â°ü¿¡ »ç¿ëÇÒ ¼öÀÖ´Â OCS Heart ½Ã½ºÅÛÀÇ ½ÃÆÇ Àü FDA ½ÂÀÎÀ» ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. µû¶ó¼­ Àå±â À̽Ŀ¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ì±¹ÀÇ Àå±â º¸Á¸ ¼Ö·ç¼Ç ½ÃÀåÀÌ È°¼ºÈ­µÇ°í ÀÖ½À´Ï´Ù. Paragonix Technologies´Â Â÷¼¼´ë ±âÁõÀÚ Æó º¸Á¸ ½Ã½ºÅÛ "BAROguard"ÀÇ FDA Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. ±âÁõÀÚ È¯ÀÚ·Î À̵¿ÇÏ´Â µ¿¾È ±âÁõÀÚ ÆóÀÇ ÃÖÀû ¿Âµµ ¹üÀ§¿Í ÀÓ»ó ÀûÀ¸·Î ±ÇÀåµÇ´Â ÆØÃ¢ ¾Ð·Â ¹üÀ§°¡ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöµË´Ï´Ù.

ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀÇ ¼öÀͰú 2031³â±îÁöÀÇ ¿¹Ãø(¹ÌÈ­ õ ´Þ·¯)

ºÏ¹Ì Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Á¦Ç°, ¿ëµµ, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°º°·Î ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº À§½ºÄܽŠ´ëÇÐ ¼Ö·ç¼Ç, Ä«½ºÅäµð¿Ã HTK, ÆÛÆÄµ¦½º, ÇÏÀÌÆ÷¼­¸ðÁ¹ µîÀ¸·Î ºÐ·ùµË´Ï´Ù.

¿ëµµº°·Î ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Á¤Àû Àú¿Â º¸Á¸, Àúü¿Â ±â°è °ü·ù, »ó¿Â ±â°è °ü·ù µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Á¤Àû Àú¿Â º¸Á¸ ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î ºÏ¹Ì Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº ½ÅÀå, °£, Æó, ½ÉÀå µîÀ¸·Î ºÐ·ùµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¼ ¶§ ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº Àå±â ÀÌ½Ä ¼¾ÅÍ, º´¿ø, Àü¹® Ŭ¸®´ÐÀ¸·Î ºÐ·ùµË´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù.

Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, 21ST Century Medicine, Bridge to Life Ltd. µîÀÌ ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀåÀÇ ¸Å·Â

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ÀÇ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀκм®
    • ÆÄ¿îµ¥ÀÌ¼Ç ¼öÄ¡ÀÇ °³¹ß
    • µ¥ÀÌÅÍÀÇ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ

Á¦4Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àå±â ÀÌ½Ä ¿ä±¸ Áõ°¡
    • ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °í¾×ÀÇ Àå±â ÀÌ½Ä ¼ö¼ú
    • Àå±âÀÇ °¡¿ë¼º Á¦ÇÑ
  • ½ÃÀå ±âȸ
    • ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • ÇâÈÄÀÇ µ¿Çâ
    • ±â°è °ü·ù ±â¼ú·ÎÀÇ À̵¿
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦5Àå Àå±â º¸Á¸ ¿ë¾× ½ÃÀå : ºÏ¹Ì ºÐ¼®

  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¼öÀÍ(2021-2031³â)
  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ¿¹Ãø ºÐ¼®

Á¦6Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - Á¦Ç°º°

  • À§½ºÄܽŠ´ëÇÐ ¼Ö·ç¼Ç
  • Ä«½ºÆ®µð¿Ã HTK
  • ÆÄÆÄµ¦½º
  • ÇÏÀÌÆ÷¼­¸ðÁ¹
  • ±âŸ

Á¦7Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - ¿ëµµº°

  • Á¤Àû Àú¿Â º¸Á¸
  • Àúü¿Â±â°è °ü·ù
  • »ó¿Â±â°è °ü·ù
  • ±âŸ

Á¦8Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - À¯Çüº°

  • ½ÅÀå
  • °£
  • Æó
  • ½ÉÀå
  • ±âŸ

Á¦9Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - ÃÖÁ¾ »ç¿ëÀÚº°

  • Àå±â ÀÌ½Ä ¼¾ÅÍ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð

Á¦10Àå ºÏ¹ÌÀÇ Àå±â º¸Á¸ ¿ë¾× ½ÃÀå ºÐ¼® - ±¹°¡º°

    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ

Á¦11Àå Àå±â º¸Á¸ ¿ë¾× ½ÃÀå - »ê¾÷ Á¤¼¼

  • ¼Ò°³
  • Àå±â º¸Á¸ ¿ë¾× ½ÃÀåÀÇ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Waters Medical Systems LLC
  • XVIVO Perfusion
  • TransMedics
  • OrganOx Limited
  • Paragonix Technologies, Inc
  • Dr. Franz Koehler Chemie GmbH
  • Accord Healthcare
  • st Century Medicine
  • Bridge to Life Ltd

Á¦13Àå ºÎ·Ï

SHW 25.07.14

The North America organ preservation solution market was valued at US$ 1,23,239.05 thousand in 2023 and is expected to reach US$ 2,26,118.82 thousand by 2031; it is estimated to register a CAGR of 8.0% from 2024 to 2031.

Rising Need for Organ Transplantation Fuels North America Organ Preservation Solution Market

Several chronic diseases are known to damage the functioning of the heart, lungs, liver, kidney, and other organs. A poor diet contributes to the development of renal and hepatic illnesses, which can also lead to organ failure. For instance, around 10% of the global population is impacted by chronic kidney disease. According to the US Department of Health & Human Services, more than 1 in 7 (i.e., ~15% or ~37 thousand adults) are estimated to have chronic kidney disease in the US. Further, excessive alcohol consumption leads to liver cirrhosis, resulting in the need for a liver transplant. The Scientific Registry of Transplant Recipients (SRTR) reports that irrespective of the success of medical treatments for heart failure, the number of candidates eligible for new heart transplants continues to rise. The COVID-19 pandemic had some impact on new listings. After a plateau from 2018 through 2020 and a slight decrease in 2020 (from 4,087 in 2019 to 4,000 in 2020), the number of new heart failure cases increased to 4,373 in 2021. Transplantation surgeries are becoming more common worldwide. In 2023, the United Network for Organ Sharing reported a record of more than 46,000 organ transplants in the US, marking an increase of over 8.7% from 2022. Additionally, the country crossed the mark of 27,000 kidney transplants for the first time in its history. Patients who are on the organ waiting list typically suffer from end-stage organ disease, which significantly affects their quality of life and may indicate that they are nearing the end of their life. The rising number of individuals with end-stage organ failure triggers the need for timely organ transplantation. Due to advancements in transplantation techniques, more such people are now eligible for organ transplants. Organ preservation solutions are used to maintain the viability and function of organs for a certain period, allowing for their transport and subsequent transplantation into a recipient. The success of organ transplantation is primarily determined by organ preservation, surgery, immunotherapy, and post-operative care. Thus, a rising demand for organ transplantation drives the organ preservation solution market toward growth.

North America Organ Preservation Solution Market Overview

The North America organ preservation solution market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging number of organ transplants are the factors benefiting the organ preservation solution market in this region. The US is the largest organ preservation solution market across the world and is estimated to dominate the global market during the forecast period. The US market growth is attributed to the rising chronic kidney diseases (CKD) prevalence and the increasing geriatric population in the US. According to the National Chronic Kidney Disease fact sheet, ~37 thousand people in the US were suffering from chronic kidney diseases in 2021.

In June 2024, the American Kidney Fund, Inc. reported that up to 37 thousand Americans have kidney disease, and ~808,000 Americans are affected by kidney failure. More than 557,000 Americans are undergoing dialysis treatment. The prevalence of kidney disease is rising and currently affects over 1 in 7 (or 14%) of American adults. In 2021, around 135,000 Americans were newly diagnosed with kidney failure. Also, 9 out of 10 people affected by kidney disease are unaware they have it, and 1 in 3 of people with severely reduced kidney function are also unaware they have kidney disease. Furthermore, as per the same source stated that more than 250,000 Americans have undergone kidney transplants, and there are over 93,000 Americans on the kidney transplant waiting list. In 2023, only 27,332 people received kidney transplants, with 6,290 of those from living donors. The rising number of approvals from the US Food and Drug Administration (FDA) and the presence of market players in the country boost the US organ preservation solution market growth. In April 2022, TransMedics Group, Inc. announced that it received premarket FDA approval for its OCS Heart System, which can be used with organs from donors after circulatory death (DCD). The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death (DCD) hearts. Thus, the rising need for organ transplantation drives the organ preservation solutions market in the US. Organ preservation solution manufacturers in the US launch devices used for organ transportation. In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system, BAROguard. The system combines Paragonix's advanced hypothermic preservation technology with automated continuous and active airway pressure control. This ensures that an optimal temperature range and a clinically recommended inflation pressure range for donor lungs are maintained throughout the journey from the donor to the recipient patient. This novel combination of advanced technologies reinforces the company's ongoing commitment to improving and redefining the standard of care within transplant medicine.

North America Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)

North America Organ Preservation Solution Market Segmentation

The North America organ preservation solution market is categorized into product, application, type, end user, and country.

Based on product, the North America organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, HypoThermosol, and others. The University of Wisconsin segment held the largest market share in 2023.

In terms of application, the North America organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.

By type, the North America organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.

Based on end user, the North America organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.

By country, the North America organ preservation solution market is segmented into the US, Canada, and Mexico. The US dominated the North America organ preservation solution market share in 2023.

Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, 21ST Century Medicine, and Bridge to Life Ltd., are among the leading companies operating in the North America organ preservation solution market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Organ Preservation Solution Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Need for Organ Transplantation
    • 4.1.2 Increasing Prevalence of Chronic Diseases
  • 4.2 Market Restraints
    • 4.2.1 Expensive Organ Transplant Surgeries
    • 4.2.2 Limited Organ Availability
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Market Players
  • 4.4 Future Trends
    • 4.4.1 Shift Toward Machine Perfusion Technique
  • 4.5 Impact of Drivers and Restraints:

5. Organ Preservation Solution Market - North America Analysis

  • 5.1 Organ Preservation Solution Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Organ Preservation Solution Market forecast Analysis

6. North America Organ Preservation Solution Market Analysis - by Product

  • 6.1 University of Wisconsin Solution
    • 6.1.1 Overview
    • 6.1.2 University of Wisconsin Solution: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.2 Custodiol HTK
    • 6.2.1 Overview
    • 6.2.2 Custodiol HTK: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.3 Perfadex
    • 6.3.1 Overview
    • 6.3.2 Perfadex: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.4 HypoThermosol
    • 6.4.1 Overview
    • 6.4.2 HypoThermosol: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

7. North America Organ Preservation Solution Market Analysis - by Application

  • 7.1 Static Cold Storage
    • 7.1.1 Overview
    • 7.1.2 Static Cold Storage: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.2 Hypothermic Machine Perfusion
    • 7.2.1 Overview
    • 7.2.2 Hypothermic Machine Perfusion: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.3 Normothermic Machine Perfusion
    • 7.3.1 Overview
    • 7.3.2 Normothermic Machine Perfusion: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

8. North America Organ Preservation Solution Market Analysis - by Type

  • 8.1 Kidneys
    • 8.1.1 Overview
    • 8.1.2 Kidneys: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.2 Liver
    • 8.2.1 Overview
    • 8.2.2 Liver: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.3 Lungs
    • 8.3.1 Overview
    • 8.3.2 Lungs: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.4 Heart
    • 8.4.1 Overview
    • 8.4.2 Heart: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

9. North America Organ Preservation Solution Market Analysis - by End User

  • 9.1 Organ Transplant Centers
    • 9.1.1 Overview
    • 9.1.2 Organ Transplant Centers: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 9.2 Hospitals
    • 9.2.1 Overview
    • 9.2.2 Hospitals: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
  • 9.3 Specialty Clinics
    • 9.3.1 Overview
    • 9.3.2 Specialty Clinics: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)

10. North America Organ Preservation Solution Market - Country Analysis

  • 10.1 North America Organ Preservation Solution Market Overview
    • 10.1.1 North America: Organ Preservation Solution Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 10.1.1.1 North America: Organ Preservation Solution Market - Revenue and forecast Analysis - by Country
      • 10.1.1.2 United States: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.2.1 United States: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.2.2 United States: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.2.3 United States: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.2.4 United States: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.3 Canada: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.3.1 Canada: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.3.2 Canada: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.3.3 Canada: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.3.4 Canada: Organ Preservation Solution Market Breakdown, by End User
      • 10.1.1.4 Mexico: Organ Preservation Solution Market - Revenue and forecast to 2031 (US$ Thousand)
        • 10.1.1.4.1 Mexico: Organ Preservation Solution Market Breakdown, by Product
        • 10.1.1.4.2 Mexico: Organ Preservation Solution Market Breakdown, by Application
        • 10.1.1.4.3 Mexico: Organ Preservation Solution Market Breakdown, by Type
        • 10.1.1.4.4 Mexico: Organ Preservation Solution Market Breakdown, by End User

11. Organ Preservation Solutions Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Organ Preservation Solutions Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Waters Medical Systems LLC
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 XVIVO Perfusion
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 TransMedics
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 OrganOx Limited
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Paragonix Technologies, Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Dr. Franz Koehler Chemie GmbH
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Accord Healthcare
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8st Century Medicine
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bridge to Life Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦